BYL719 (alpelisib) for the treatment of PIK3CA-mutated, recurrent/advanced cervical cancer.

Giorgio BoganiValentina ChiappaMarta BiniDominique RonzulliAlice IndiniElena ConcaFrancesco Raspagliesi

Published in: Tumori (2022)

Our preliminary data highlighted a high level of efficacy in this setting of patients. Further trials are needed to assess the safety and effectiveness of alpelisib in PIK3CA-mutated recurrent/advanced cervical cancer.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
randomized controlled trial
systematic review
peritoneal dialysis
electronic health record
big data
combination therapy
wild type
smoking cessation